Category - Developments

Developments

Polyrizon files patent application with ILPO for T&T technology

Polyrizon (NASDAQ:PLRZ) has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO). The company stated...

January 30, 2025

Developments

Model Medicines unveils AI-driven pipeline breakthrough; demonstrates end-to-end drug discovery capabilities

Closely held Model Medicines has announced the unveiling of a generative AI-driven, multi-modal therapeutic pipeline breakthrough, showcasing its end-to-end drug discovery capabilities for novel target discovery...

January 28, 2025

Developments

NLS launches preclinical program for Mazindol ER in fentanyl addiction

NLS Pharmaceutics (NASDAQ:NLSP; NASDAQ:NLSPW) has announced the launch of a preclinical program to evaluate Mazindol ER as a novel treatment for fentanyl dependence. According to the Centers for Disease Control and...

January 28, 2025

Developments

Conduit partners with Sarborg to advance drug development with AI

Conduit Pharmaceuticals (NASDAQ:CDT) has announced that the first phase in its collaboration with Sarborg, aimed at integrating advanced AI and cybernetics technology into its operations has been completed. The company...

January 28, 2025

Developments

Stereotaxis receives CE Mark for cardiac ablation catheter

Stereotaxis (NYSE:STXS) has announced that it has received European CE Mark approval for its MAGIC ablation catheter, designed to perform cardiac ablation procedures aimed at treating heart arrhythmia. According to...

January 27, 2025

Developments

RenovoRX highlights abstract showcasing promising PK data for TAMP in LAPC

RenovoRX (NASDAQ:RNXT) has announced that an abstract presented at the ASCO Gastrointestinal Cancers Symposium 2025 highlights promising pharmacokinetic (PK) data from its patented Trans-Arterial Micro-Perfusion (TAMP)...

January 27, 2025

Developments

Veru reports positive topline results of Phase 2b study of enobosarm for weight loss

Veru (NASDAQ:VERU) has announced positive topline results from its Phase 2b QUALITY clinical study evaluating the safety and efficacy of enobosarm in patients receiving WEGOVY (semaglutide) for weight reduction...

January 27, 2025

Developments

Social Capital’s Chamath Palihapitiya calls out Perimeter’s AI-driven cancer margin visualization technology on X show

Chamath Palihapitiya Renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, Chamath Palihapitiya, sat down with Tucker Carlson today to talk about several topics, including AI’s...

January 24, 2025

Developments

Greenwich adds Harvard and Johns Hopkins sites to Phase 3 trial

Greenwich LifeSciences (NASDAQ:GLSI) has announced the launch of two new clinical sites for its FLAMINGO-01 Phase 3 trial of GLSI-100 in HER2 breast cancer, including Harvard and Johns Hopkins Universities...

January 23, 2025

Developments

EMA grants IRLAB waiver from pediatric studies of mesdopetam in PD

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that the European Medicines Agency (EMA) has granted a waiver allowing the company to bypass pediatric studies of mesdopetam, enabling a focus on patient groups...

January 23, 2025

Category - Developments

Subscribe